US Patent

US9511031 — Controlled release doxycycline

Formulation · Assigned to Mayne Pharma International Pty Ltd · Expires 2034-10-23 · 8y remaining

Vulnerability score 42/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects controlled release compositions of doxycycline that exhibit a superior dissolution profile and reduced side effects.

USPTO Abstract

The disclosure provides controlled release compositions comprising tetracyclines and in some embodiments, doxycycline. The controlled release doxycycline compositions of the invention exhibit a superior dissolution profile and provide reduced side effects such as nausea and irritation.

Drugs covered by this patent

doxycycline-hyclate (DOXYCYCLINE HYCLATE)

Patent Metadata

Patent number: US9511031
Jurisdiction: US
Classification: Formulation
Expires: 2034-10-23
Drug substance claim: No
Drug product claim: Yes
Assignee: Mayne Pharma International Pty Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.